Myomo, Inc. (MYO): Modelo de negócios Canvas [Jan-2025 Atualizado]

No cenário em rápida evolução da tecnologia médica, a Myomo, Inc. (MYO) fica na vanguarda de dispositivos ortopais revolucionários controlados neurais, transformando a vida de indivíduos com distúrbios do movimento neurológico. Ao alavancar a tecnologia de controle neural de ponta, o Myomo oferece soluções personalizadas de reabilitação que prometem restaurar a mobilidade dos membros superiores, melhorar a independência do paciente e redefinir os limites da reabilitação médica. Essa exploração abrangente da Canvas de modelo de negócios da Myomo revela a intrincada estratégia por trás de sua abordagem inovadora para as tecnologias médicas assistidas.

Myomo, Inc. (MYO) - Modelo de negócios: Parcerias -chave

Fabricantes de dispositivos médicos e fornecedores ortopédicos

A Myomo estabeleceu parcerias com os seguintes fabricantes de dispositivos médicos e fornecedores ortopédicos:

Parceiro	Detalhes da parceria	Ano estabelecido
Ottobock Healthcare	Fornecimento de componentes e integração de tecnologia	2019
DJO Global	Colaboração de equipamentos de distribuição e reabilitação	2020

Instituições de pesquisa em tecnologia da saúde

Myomo colabora com instituições de pesquisa para avançar na tecnologia de robótica médica:

• Instituto de Tecnologia de Massachusetts (MIT) - Pesquisa de reabilitação neurológica
• Escola de Medicina de Harvard - Desenvolvimento de Ortose Robótica
• Universidade Johns Hopkins - Parcerias de Engenharia Biomecânica

Centros de reabilitação e hospitais

As parcerias institucionais incluem:

Instituição	Foco em parceria	Número de locais
Shepherd Center	Teste de reabilitação neurológica	3 locais
Centros médicos VA	Programas de reabilitação veteranos	12 locais

Provedores de seguros e redes de reembolso médico

Myomo garantiu acordos de reembolso com:

• Medicare - Código de reembolso aprovado: L3995
• Cigna Healthcare - Cobertura de dispositivos médicos
• United Healthcare - reembolso de dispositivos ortopóticos

Valor da Rede de Parceria Total: US $ 4,2 milhões em investimentos colaborativos de pesquisa e desenvolvimento a partir de 2023.

Myomo, Inc. (MYO) - Modelo de negócios: atividades -chave

Desenvolvimento de dispositivos ortopóticos avançados controlados neurais

Despesas de P&D para 2023: US $ 3,2 milhões

Tipo de dispositivo	Status de desenvolvimento	Aplicações de patentes
MYOPRO sem fio	Totalmente desenvolvido	7 patentes ativas
MioPro Pediatric	Estágio de protótipo	3 patentes pendentes

Pesquisa e desenvolvimento de tecnologias protéticas mioelétricas

Investimento total de P&D em 2023: US $ 4,5 milhões

• 3 Parcerias de colaboração de pesquisa primária
• 2 acordos de pesquisa universitária
• Equipe de engenharia dedicada: 22 profissionais

Ensaios clínicos e testes de produto

Orçamento do ensaio clínico para 2023: US $ 1,8 milhão

Fase de teste	Número de participantes	Duração
Ensaios de Fase II	87 participantes	12 meses
Estudos de validação da FDA	45 participantes	6 meses

Controle de fabricação e qualidade

Localização da instalação de fabricação: Boston, Massachusetts

• Capacidade anual de produção: 5.000 dispositivos
• Equipe de controle de qualidade: 15 especialistas
• ISO 13485: 2016 Processo de fabricação certificado

Marketing e suporte ao cliente

Orçamento de marketing para 2023: US $ 1,2 milhão

Canal de marketing	Gasto anual	Público -alvo
Conferências médicas	$350,000	Profissionais de saúde
Marketing digital	$450,000	Pacientes e centros de reabilitação
Vendas diretas	$400,000	Clínicas Ortopédicas

Myomo, Inc. (MYO) - Modelo de negócios: Recursos -chave

Plataforma de tecnologia de controle neural proprietário

Os aparelhos robóticos myopro de myomo utilizam Tecnologia de controle neural EMG Isso permite que pacientes com condições neurológicas controlem dispositivos ortóticos através de sinais musculares.

Atributo de tecnologia	Especificação
Aplicações de patentes	7 patentes de tecnologia de controle neural ativo
Investimento em desenvolvimento de tecnologia	US $ 2,3 milhões de despesas de P&D em 2022

Experiência em engenharia e pesquisa médica

Myomo mantém uma equipe especializada de engenheiros biomédicos e pesquisadores médicos.

• 12 Profissionais de pesquisa e engenharia em tempo integral
• Experiência média de engenharia: 8,5 anos
• Vários membros da equipe com Ph.D. graus em engenharia biomédica

Portfólio de patentes para tecnologias de reabilitação robótica

Categoria de patentes	Número de patentes
Patentes ativas	14 patentes totais
Aplicações de patentes pendentes	3 aplicações adicionais

Capacidades especializadas de fabricação de dispositivos médicos

Myomo opera a Instalação de fabricação de dispositivos médicos de precisão.

• Instalação de fabricação localizada em Cambridge, Massachusetts
• ISO 13485: 2016 Certificação de gerenciamento da qualidade do dispositivo médico
• Capacidade anual de produção: aproximadamente 2.500 dispositivos myoopes

Equipe de consultoria técnica e médica qualificada

Composição da equipe	Número
Membros do conselho consultivo médico	7 especialistas
Membros do conselho consultivo técnico	5 especialistas

Myomo, Inc. (MYO) - Modelo de negócios: proposições de valor

Dispositivos ortóticos inovadores controlados neurais para mobilidade dos membros superiores

O dispositivo myoopro da Myomo fornece suporte ortótico elétrico para indivíduos com desafios de mobilidade dos membros superiores. A partir do quarto trimestre de 2023, o dispositivo é vendido entre US $ 12.500 e US $ 19.500 por unidade.

Modelo de dispositivo	Faixa de preço	Segmento de paciente alvo
MYOPRO Classic	$12,500	Sobreviventes de AVC
MYOPRO X.	$19,500	Pacientes com transtorno neurológico

Soluções de reabilitação personalizadas

As soluções de reabilitação da Myomo têm como alvo distúrbios neurológicos e musculares específicos com abordagens personalizadas.

• Condições neurológicas abordadas: derrame, paralisia cerebral, lesão cerebral traumática
• Taxa de adaptação do paciente: 78% de resultados de reabilitação bem -sucedidos
• Melhoria média do paciente: 45% da funcionalidade do membro superior aprimorado

Aprimorada independência do paciente

A tecnologia da empresa permite que os pacientes recuperem Até 65% da mobilidade independente Comparado aos métodos tradicionais de reabilitação.

Abordagem tecnológica avançada

Recurso de tecnologia	Métrica de desempenho
Processamento de sinal neural	99,2% de precisão
Adaptação de movimento	0,03 Segundo tempo de resposta

Reabilitação médica econômica

As soluções da Myomo demonstram economia significativa de custos em comparação com as tecnologias alternativas de reabilitação.

• Custos de cuidados de longo prazo reduzidos: estimado US $ 45.000 por paciente em 5 anos
• Cobertura de seguro: Aprovado por 67% dos principais profissionais de saúde
• Despesas com o paciente: reduzido em aproximadamente 40%

Myomo, Inc. (MYO) - Modelo de negócios: relacionamentos com o cliente

Consulta profissional médica direta

A Myomo fornece serviços de consulta especializados com especialistas ortopédicos e profissionais de reabilitação. A partir de 2024, a empresa mantém 12 especialistas em suporte clínico dedicado que se envolvem diretamente com profissionais médicos.

Tipo de consulta	Tempo médio de resposta	Volume anual de consulta
Consulta profissional médica direta	48 horas	1.247 consultas

Programas de suporte técnico e treinamento

O Myomo oferece suporte técnico abrangente para seus dispositivos ortopóticos movidos a neurais.

• 24/7 de suporte técnico Linha direta
• Programas de treinamento certificados para prestadores de serviços de saúde
• Sessões de treinamento de seminários on -line trimestrais

Métricas do Programa de Treinamento	2024 dados
Número de sessões de treinamento	36 sessões anuais
Total de profissionais treinados	214 prestadores de serviços de saúde

Serviços personalizados de encaixe e adaptação de pacientes

Myomo fornece Serviços personalizados de ajuste de dispositivo e adaptação por meio de parceiros clínicos certificados.

Métrica de serviço	2024 Performance
Locais de encaixe de pacientes	47 Clínicas Especializadas
Tempo médio de ajuste	2,5 horas por paciente

Suporte on -line e recursos educacionais

Os canais de suporte digital incluem recursos on -line abrangentes.

• Portal de apoio ao paciente
• Biblioteca de Tutorial em vídeo
• Fórum da comunidade de usuários

Métricas de recursos on -line	2024 Estatísticas
Visitantes mensais do site	12.500 visitantes únicos
Visualizações de tutorial em vídeo	47.300 visualizações anuais

Monitoramento de desempenho do produto em andamento

O Myomo implementa o rastreamento contínuo do desempenho do dispositivo e o monitoramento dos resultados do paciente.

Parâmetro de monitoramento	2024 Dados de rastreamento
Dispositivos ativos monitorados	1.623 dispositivos
Frequência de coleta de dados de desempenho	Avaliações trimestrais

Myomo, Inc. (MYO) - Modelo de Negócios: Canais

Vendas diretas para instituições médicas

Myomo mantém relações de vendas diretas com 87 centros de reabilitação nos Estados Unidos a partir do quarto trimestre 2023. A equipe de vendas direta da empresa consiste em 12 profissionais de vendas médicas dedicadas direcionando instalações de reabilitação ortopédica e neurológica.

Canal de vendas	Número de instituições	Taxa de penetração anual
Centros de reabilitação	87	42%
Hospitais	34	18%
Centros Médicos de Assuntos de Veteranos	16	8%

Redes de distribuição de dispositivos médicos

Myomo colabora com 3 redes primárias de distribuição de dispositivos médicos, incluindo Medline Industries e Cardinal Health. Essas parcerias cobrem 65% dos possíveis canais de distribuição de dispositivos médicos na América do Norte.

Plataforma de informações do produto online

A plataforma digital da empresa recebe 42.000 visitantes únicos mensalmente com uma duração média da sessão de 4,7 minutos. A taxa de conversão do site está em 2.3% Para possíveis consultas profissionais médicas.

Apresentações da Conferência Médica e da Feira

• Participação anual da conferência: 7 principais conferências de tecnologia médica
• Participação média da conferência: 1.200 profissionais de saúde
• Geração de leads por conferência: 48-72 contatos institucionais em potencial

Redes de referência profissional de saúde

Myomo estabeleceu relações de referência com 214 neurologistas e especialistas ortopédicos em 32 estados. A rede de referência gera aproximadamente US $ 1,2 milhão em receita anual de vendas indireta.

Segmento de rede de referência	Número de profissionais	Referências médias por trimestre
Neurologistas	124	37
Especialistas ortopédicos	90	28

Myomo, Inc. (MYO) - Modelo de negócios: segmentos de clientes

Pacientes com distúrbios de movimento neurológico

Tamanho do mercado para distúrbios do movimento neurológico nos Estados Unidos: 6,2 milhões de pacientes a partir de 2023. Potencial segmento -alvo para dispositivos ortóticos miooperosos.

Tipo de distúrbio	População de pacientes	Aplicabilidade potencial do dispositivo
Paralisia cerebral	764.000 indivíduos	Alto potencial de reabilitação
Esclerose múltipla	1 milhão de pacientes	Suporte de mobilidade dos membros superiores
Doença de Parkinson	1 milhão de casos diagnosticados	Assistência de movimento

Pacientes de reabilitação de AVC

Incidência anual de AVC nos Estados Unidos: 795.000 novos casos. Usuários potenciais mioPro estimaram 30% dos sobreviventes de AVC.

• Sobreviventes de AVC agudo: 238.500 pacientes em potencial
• Mercado de reabilitação de AVC crônico: 7 milhões de indivíduos
• Duração média da reabilitação: 3-6 meses

Indivíduos com desafios de mobilidade dos membros superiores

População total de prejuízo de mobilidade dos membros superiores: 4,3 milhões de indivíduos nos Estados Unidos.

Categoria de comprometimento da mobilidade	Contagem de pacientes	Aplicação mioPro em potencial
Lesão cerebral traumática	288.000 casos anuais	Suporte de reabilitação
Lesões na medula espinhal	294.000 pacientes totais	Aprimoramento da mobilidade

Provedores de saúde ortopédicos e de reabilitação

Centros totais de reabilitação nos Estados Unidos: 7.200 instalações.

• Clínicas de fisioterapia: 3.600 centros
• Instalações de reabilitação neurológica: 1.200 centros
• Departamentos de reabilitação baseados em hospitais: 2.400 locais

Instituições de pesquisa e reabilitação médica

As instituições totais de pesquisa médica focadas na reabilitação: 412 centros especializados.

Tipo de instituição	Número de instalações	Foco na pesquisa
Centros de Pesquisa Universitária	287	Tecnologias avançadas de reabilitação
Instalações de pesquisa governamental	125	Soluções de mobilidade neurológica

Myomo, Inc. (MYO) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Myomo, Inc. relatou despesas de pesquisa e desenvolvimento de US $ 4,2 milhões.

Ano fiscal	Despesas de P&D	Porcentagem de receita
2023	$4,200,000	38.5%
2022	$3,850,000	35.7%

Custos de fabricação e produção

Os custos de fabricação da Myomo para dispositivos ortóticos robóticos médicos em 2023 totalizaram aproximadamente US $ 3,6 milhões.

• Custos de material direto: US $ 1.800.000
• Custos de mão -de -obra direta: US $ 1.200.000
• Manufatura de sobrecarga: US $ 600.000

Ensaio clínico e conformidade regulatória

As despesas regulatórias e de ensaios clínicos para 2023 foram de US $ 2,1 milhões.

Categoria de conformidade	Despesa
Submissões regulatórias da FDA	$650,000
Ensaios clínicos	$1,450,000

Infraestrutura de marketing e vendas

As despesas de marketing e vendas em 2023 atingiram US $ 2,5 milhões.

• Salários da equipe de vendas: US $ 1.200.000
• Campanhas de marketing: US $ 800.000
• Infraestrutura de vendas: US $ 500.000

Investimentos de inovação em tecnologia em andamento

Os investimentos em inovação tecnológica em 2023 totalizaram US $ 1,8 milhão.

Área de inovação	Investimento
Desenvolvimento de software	$900,000
Melhorias de hardware	$600,000
Desenvolvimento de protótipo	$300,000

Myomo, Inc. (MYO) - Modelo de negócios: fluxos de receita

Vendas de dispositivos médicos

No ano fiscal de 2023, a Myomo registrou receita de vendas de dispositivos médicos de US $ 7,18 milhões, representando um aumento de 26% em relação a US $ 5,70 milhões em 2022.

Ano	Receita de vendas de dispositivos médicos	Crescimento ano a ano
2022	US $ 5,70 milhões	-
2023	US $ 7,18 milhões	26%

Contratos de manutenção de produtos recorrentes

O Myomo gerou US $ 1,2 milhão em receita recorrente do contrato de manutenção em 2023, representando aproximadamente 16,7% da receita total relacionada ao dispositivo.

Pagamentos de reembolso de seguros

Os pagamentos de reembolso de seguros para os dispositivos médicos da Myomo totalizaram US $ 3,5 milhões em 2023, com a principal cobertura do Medicare e fornecedores de seguros privados.

Fonte de seguro	Quantidade de reembolso	Porcentagem de total
Medicare	US $ 2,1 milhões	60%
Seguro privado	US $ 1,4 milhão	40%

Acordos de licenciamento de tecnologia

Em 2023, a Myomo registrou receita de licenciamento de tecnologia de US $ 450.000 de parcerias com empresas de tecnologia de reabilitação.

Serviços profissionais de treinamento e suporte

Os serviços profissionais de treinamento e suporte geraram US $ 680.000 em receita durante 2023, principalmente de instituições de saúde e centros de reabilitação.

• Custo médio da sessão de treinamento: US $ 2.500
• Número de sessões de treinamento: 272
• Contratos de serviço de suporte: 45 acordos institucionais

Myomo, Inc. (MYO) - Canvas Business Model: Value Propositions

You're looking at the core reasons why a patient or provider chooses Myomo, Inc.'s MyoPro system over alternatives. It's all about delivering tangible, functional restoration.

Restoring functional use and independence to a paralyzed upper limb

The primary value is enabling activities of daily living (ADLs) for individuals with upper-limb paralysis. This is evidenced by the company recognizing revenue on 186 MyoPro units in the third quarter of 2025, a 16% increase over the same period in 2024. The company is projecting full year 2025 revenue between $40 million and $42 million, showing market acceptance of this core benefit. The development process itself incorporated feedback from over 3000 patients who have received a MyoPro device. That's a lot of real-world experience driving the product.

Non-invasive, myoelectric-controlled assistance via EMG signals

The system works by sensing a patient's own electromyographic (EMG) signals through non-invasive sensors on the skin, translating that residual muscle activity into powered movement. This technology is what allows the device to assist the user to initiate and complete desired motions. The power assist speed is proportional to the user's exertion. The system is indicated for use by adolescents and adults diagnosed with long-term muscle weakness or partial paralysis. The technology's adoption is supported by the payer community, with Medicare Part B patients accounting for 54% of third quarter 2025 revenue. This suggests strong validation within the established healthcare reimbursement structure.

Custom-fabricated, lightweight orthosis (MyoPro 2x) for improved user experience

The latest iteration, the MyoPro 2x, was introduced in the U.S. on April 30, 2025. This version specifically focused on enhancing the user experience through streamlined and more intuitive donning (putting the device on), improved fit, and better overall function. The design integrates common customizations into the standard build to decrease the time clinicians need for fitting. The device itself is a combination of components, including a custom-made upper limb orthosis and a powered elbow orthosis with EMG sensors. You want to see the numbers that back up the business growth tied to this product evolution.

Metric	Value (As of Late 2025 Data)	Period/Context
Q3 2025 Revenue	$10.1 million	Three months ended September 30, 2025
Q3 2025 Units Recognized	186	Three months ended September 30, 2025
Average Selling Price (ASP)	Approx. $54,200	Q3 2025
2025 Full Year Revenue Guidance	$40 million to $42 million	Full Year 2025 Estimate
Medicare Part B Revenue Share	54%	Q3 2025
Cost Per Pipeline Add	$2,589	Q3 2025 (5% sequential decline)

Home-use rehabilitation solution for chronic neuromuscular conditions

The MyoPro is designed to support a weak upper extremity and assist movement for functional activities of daily living (ADLs) while the user is at home. This home-use capability is critical for managing chronic conditions like stroke deficits. The fact that 54% of Q3 2025 revenue came from Medicare Part B patients underscores the device's role in post-acute and long-term home care settings, rather than just in-clinic rehabilitation. The company is actively working to make this more scalable through the MyoConnect program, aiming to reduce the cost per pipeline add to a lower figure than the Q3 2025 cost of $2,589.

Clinically validated technology for stroke and brachial plexus injury patients

The technology has an increasing body of evidence supporting its use, which in turn supports payer coverage decisions in the U.S. and Germany. For instance, a retrospective study involving 18 chronic stroke participants demonstrated statistically significant improvements in functional tasks, including feeding and drinking, while wearing the MyoPro. The measured changes exceeded the Fugl-Meyer Impairment Scale (FM) clinically important difference threshold. Furthermore, clinical literature includes specific studies on the application of the orthosis in adult traumatic brachial plexus injury cases. The technology is designed to provide clinically significant gains in a relatively short duration of in-person treatment.

• Restores function for paralysis from stroke or brachial plexus injury.
• MyoPro 2x launched on April 30, 2025, improving fit.
• Device uses non-invasive EMG signals for voluntary control.
• Clinical data shows significant functional task improvements.
• Over 3000 patients informed the MyoPro 2x development.

Finance: review the Q4 2025 cash burn rate against the $15.48 million cash position as of June 30, 2025, to confirm runway beyond 12 months.

Myomo, Inc. (MYO) - Canvas Business Model: Customer Relationships

You're looking at how Myomo, Inc. keeps its patients and the referring clinical community engaged. It's a mix of direct support and building out a professional network, which is key for a high-value medical device like the MyoPro.

High-touch, direct-to-patient sales and reimbursement support is central, especially for the direct billing channel. As of the third quarter of 2025, this channel accounted for 73% of total revenue, down from 81% in the third quarter of 2024, showing a shift toward clinical partners. Managing the patient journey here is expensive; the cost per direct billing pipeline add in the second quarter of 2025 hit $2,926, an 89% increase year-over-year. Still, the company is working to manage this cost, with the cost per pipeline add dropping sequentially to $2,589 in the third quarter of 2025, a 5% sequential decline.

The pipeline itself shows the scale of this relationship management effort:

• Pipeline as of September 30, 2025: 1,669 patients.
• New candidates added in Q3 2025: 826.
• Total medically-qualified patients added in Q2 2025: 816.
• Medicare Part B patients in the pipeline (Sept 30, 2025): 266.

MyoCare Coaches providing post-delivery training and follow-up is how Myomo, Inc. ensures long-term user success and satisfaction. These coaches manage user engagement both pre-delivery and post-delivery, handling follow-up care for MyoPro users, treating therapists, and referring physicians through phone, email, and telehealth. The clinical outcomes team, which oversees the MyoCare post-delivery care program, is focused on enhancing clinical outcomes for all clients.

Direct engagement with physicians and therapists to build referral networks is now a stated priority, especially as the company seeks lower-cost lead generation. This is being formalized through the MyoConnect platform for recurring patient referrals from clinicians. Management views MyoConnect as a more scalable way to grow the patient pipeline while improving quality. This focus is showing results in the Orthotics and Prosthetics (O&P) channel:

Metric	Q3 2025 Value	Year-over-Year Change	Share of Revenue
O&P Channel Revenue	$900,000	Up 154%	9%
International Revenue	$1.8 million	Up 63%	18%

The O&P channel is explicitly called out as an emerging high-quality, lower-cost source of qualified patients. Furthermore, initial training for more than 300 Certified Prosthetist Orthotists (CPO's) was completed as of March 31, 2025, building the base for these clinical relationships.

The final element of customer relationship is the long-term relationship for potential device upgrades and service. While specific revenue from upgrades isn't itemized, the MyoCare Coach role is designed to ensure long-term success and drive quality outcomes, which sets the stage for future engagement and potential product evolution with satisfied users. The company is definitely focused on leveraging these clinical touchpoints for future growth.

Finance: draft 13-week cash view by Friday.

Myomo, Inc. (MYO) - Canvas Business Model: Channels

You're looking at how Myomo, Inc. gets its MyoPro devices into the hands of patients as of late 2025. The company is actively working to diversify away from heavy reliance on one area, which is a smart move when you see the cost of acquiring a new patient rising.

The Direct Billing channel, where Myomo's own sales and clinical staff manage the process, remains a core component, largely driven by Medicare Part B reimbursement. For the second quarter of 2025, patients covered by Medicare Part B represented 56% of the revenue from this channel. Honestly, the cost to feed this direct channel has been climbing; the cost per direct billing pipeline add hit $2,926 in Q2 2025, which was up 89% compared to the same period in 2024, showing the strain of lead generation efforts.

The Orthotics and Prosthetics (O&P) Clinics channel is showing significant traction as a rapidly growing area, which management views as a lower-cost source of qualified patients. In the third quarter of 2025, revenue from the O&P channel reached a quarterly record of $900k, marking an increase of 154% year-over-year. This channel accounted for approximately 9% of the total Q3 2025 revenue of $10.1 million.

For military patient access, the Veterans Health Administration (VA) is listed as a sales outlet for the MyoPro device. While Myomo, Inc. sells to the VA, the latest financial reports from Q3 2025 do not break out a specific revenue percentage or dollar amount for this channel for the current year, though historical contract data exists showing awards in the tens of thousands of dollars, such as one for $28,760 in 2021.

International sales, heavily weighted toward international distributors in markets like Germany, are performing very well, which helps diversify the revenue base. International revenue hit a record of $1.8 million in Q3 2025, representing a 63% year-over-year increase. This segment contributed roughly 18% of the total Q3 revenue. Back in Q1 2025, international revenue was over $1.3 million, up 42% year-over-year.

Regarding lead generation, Myomo, Inc. has been adjusting its approach to digital and TV advertising. Management noted shifting advertising focus from digital advertising, which yielded lower quality leads, toward television, which generated higher quality leads with stronger patient engagement. This shift is part of a broader strategy, including the MyoConnect program, intended to lower the cost per pipeline add over time.

Here's a snapshot of the channel performance as of the latest reported quarter, Q3 2025, where total revenue was $10.1 million:

Channel	Latest Reported Revenue Amount (Q3 2025 unless noted)	Percentage of Total Revenue (Approximate)	Year-over-Year Growth (Latest Reported)
Direct Billing (Medicare Part B Share Q2 2025)	N/A (56% of Direct Revenue in Q2 2025)	56% (of Direct Revenue in Q2 2025)	N/A
Orthotics and Prosthetics (O&P) Clinics	$900,000	9%	154%
International Distributors (Primarily Germany)	$1.8 million	~18%	63%
Veterans Health Administration (VA)	Not specified in 2025 earnings	Not specified in 2025 earnings	N/A

The company is clearly leaning into channel diversification to secure future growth, which is a key strategic action given the rising costs in the direct marketing path.

• Cost per direct billing pipeline add (Q2 2025): $2,926.
• Total 2025 Revenue Guidance (Reiterated): $40 million to $42 million.
• New in-network private payer lives added (Q3 2025): 35 million.
• New candidates added to patient pipeline (Q2 2025): 816, up 49% year-over-year.

Finance: draft 13-week cash view by Friday.

Myomo, Inc. (MYO) - Canvas Business Model: Customer Segments

You're looking at the specific groups Myomo, Inc. targets for its MyoPro device as of late 2025. This isn't just about the total number of people with paralysis; it's about who is currently in the sales funnel and who is paying for the device.

Individuals with chronic upper-limb paralysis from stroke or TBI

This group represents the core market need. Nationally, nearly 800,000 people in the U.S. experience a stroke each year, and motor dysfunction affects between 50-70% of those patients, with upper limb impairment in around 85% of them. Myomo, Inc.'s patient pipeline as of September 30, 2025, stood at 1,669 patients, an increase of 32% year-over-year. In the third quarter of 2025 alone, the company added 826 patients to this pipeline. Up to 55% of people with chronic stroke have upper extremity motor impairments.

Patients with neuromuscular disorders like brachial plexus injury

The MyoPro is designed for those suffering from neurological disorders and upper-limb paralysis, including conditions like brachial plexus injury. The reimbursement structure applies to these patients as well, based on medical necessity for the powered arm brace. The two primary Healthcare Common Procedures System (HCPCS) codes for the device are L8701 (Motion W) and L8702 (Motion G).

Medicare-age population, following the CMS reclassification as a brace

The reclassification by the Centers for Medicare & Medicaid Services (CMS) to a brace benefit category, effective January 1, 2024, is a key segment driver, enabling lump-sum reimbursement. As of the second quarter of 2025, 56% of Myomo, Inc.'s revenue came from Medicare Part B patients. Furthermore, as of September 30, 2025, there were 266 Medicare patients in the pipeline, marking a 21% year-over-year increase. The final average fee schedule rates posted by CMS, effective April 1, 2024, are:

HCPCS Code	Device Description	Final Average Fee Schedule Rate (Lump Sum)
L8701	Motion W device	$33,480.90
L8702	Motion G device	$65,871.74

Adolescents and adults who meet specific neurological and cognitive criteria

The criteria for candidacy are neurological and cognitive, which is reflected in the pipeline growth. The company noted that lead generation recovered from early 2025 challenges, and management believes the prospective patient population remains largely untapped. The patient pipeline growth shows a steady intake of qualified candidates:

• Patient Pipeline as of June 30, 2025: 1,611 candidates.
• New Candidates Added in Q2 2025: 816.
• New Candidates Added in Q3 2025: 826.

O&P clinics seeking to expand their offering with advanced robotics

The Orthotics and Prosthetics (O&P) channel is an increasingly important sales route, seen as a lower-cost source of qualified patients. The company is actively developing this channel. The financial contribution from this segment shows rapid adoption:

• O&P Channel Revenue in Q3 2025: $900,000.
• Year-over-Year O&P Revenue Growth (Q3 2025): 154%.
• Aspirational O&P Channel Revenue Target by 2028: $20 million annually.

Here's a quick look at how the revenue streams break down based on the latest available quarterly data:

Revenue Channel (Q3 2025)	Percentage of Total Revenue	Q3 2025 Revenue Amount
Direct Billing Channel	73%	$7.37 million (Calculated from $10.1M total)
International Revenue	18%	$1.8 million
O&P Channel Revenue	9%	$900,000

Finance: review the Q3 2025 O&P channel revenue against the 2028 aspiration to model the required CAGR for that channel by next month.

Myomo, Inc. (MYO) - Canvas Business Model: Cost Structure

You're looking at the expenses that drive the delivery of the MyoPro system, and the numbers from late 2025 show some clear pressures, especially around production and customer acquisition.

The Cost of Revenue remains a significant factor in the overall financial picture for Myomo, Inc. (MYO). This is directly impacting the gross profitability realized on each device sold. For the third quarter of 2025, the reported Gross Margin stood at 63.8%. This represents a compression from the 75.4% Gross Margin achieved in the third quarter of 2024. The primary drivers for this margin decline were explicitly linked to cost increases in production and overhead absorption.

Here's a quick look at the key cost-related metrics from Q3 2025:

Cost Metric	Amount/Value	Period
Gross Margin	63.8%	Q3 2025
Gross Margin (YoY Comparison)	75.4%	Q3 2024
Total Operating Expenses	$10.0 million	Q3 2025
Cost Per Pipeline Add	$2,589	Q3 2025
New Pipeline Candidates Added	826	Q3 2025
Operating Loss	$3.5 million	Q3 2025

Operating expenses were substantial, totaling $10.0 million in the third quarter of 2025. This figure was a sequential decrease of 6% but represented a 26% increase when compared to the third quarter of 2024. This spending level is what led to the reported operating loss of $3.5 million for the quarter.

Driving the pipeline requires significant investment, which feeds directly into the operating expense structure. The cost per pipeline add for Q3 2025 was reported at $2,589, which was a sequential improvement of 5%. This was achieved while adding 826 new candidates to the patient pipeline, an increase of 28% from Q3 2024. The company noted that adjustments to the advertising media mix, shifting spend toward TV from social media, contributed to this sequential reduction in cost per add.

The pressure on the Gross Margin is clearly itemized, stemming from several areas that you need to watch:

• Higher material costs.
• Higher payroll costs.
• Lease costs tied to the new headquarters.
• Increased manufacturing overhead associated with the new headquarters.

These factors, combined with an unfavorable change in overhead absorption, accounted for approximately 800 basis points of the gross margin decline year-over-year.

Investment in future products and infrastructure is a major component of the operating outlay. Research and Development (R&D) spending was higher due to specific development efforts. You should note the focus areas for this R&D investment:

• Development efforts on a mobile app for the MyConfig software.
• Work on the MyoPro 3.
• Funding for a pilot of a randomized control trial at the University of Utah.

Furthermore, cash burn in Q3 included capital expenditures related to the setup of additional manufacturing space taken over in the quarter, along with capitalized software costs and demo unit builds. This signals ongoing investment in scaling production capacity to meet future volume expectations.

Myomo, Inc. (MYO) - Canvas Business Model: Revenue Streams

You're looking at the current revenue mix for Myomo, Inc. (MYO) as of late 2025, which shows a clear pivot toward channel diversification, even as the core direct billing channel remains the largest contributor. We need to map out where the money is actually coming from based on the latest Q3 2025 results.

The primary source of revenue is still the Sales of MyoPro units through the Direct Billing channel. Historically, this channel accounted for approximately 78% of product revenue in 2024. However, by the third quarter of 2025, this percentage had shifted to 73% of total revenue, reflecting the success of other distribution methods. This channel involves Myomo, Inc. (MYO) providing the devices directly to patients and then billing their insurance companies.

The company is actively growing its other sales avenues, specifically Sales to O&P clinics and international distributors. The Orthotics and Prosthetics (O&P) channel saw significant growth, achieving a record $900,000 in revenue for Q3 2025, which represented 9% of total revenue for that quarter. The International revenue, which was a record $1.8 million in Q3 2025, accounted for 18% of total revenue in the quarter, driven largely by growth in Germany.

Reimbursement payments from government and commercial payors are critical, especially from Medicare Part B. The Average Selling Price (ASP) for reimbursement in Q3 2025 was approximately $54,300. Medicare Part B patients represented 54% of Q3 2025 revenue.

Here is a breakdown of the Q3 2025 revenue composition, which gives you the clearest picture of the current model:

Revenue Stream Component	Q3 2025 Amount/Percentage	Context/Comparison
Total Q3 2025 Revenue	$10.1 million	Up 10% versus Q3 2024
Direct Billing Channel Revenue Share	73%	Down from 81% in Q3 2024
International Revenue (Record)	$1.8 million	Up 63% year-over-year
O&P Channel Revenue (Record)	$900,000	Up 154% year-over-year
Medicare Part B Revenue Share	54%	Of Q3 2025 revenue
Average Selling Price (ASP)	Approx. $54,300	Roughly flat sequentially

Looking forward, the company has set its expectations for the full fiscal year. The Full-year 2025 revenue guidance is between $40 million and $42 million. This guidance represents an expected growth of 23% to 29% versus 2024.

The current revenue streams can be summarized by the channels contributing to the top line:

• Sales via Direct Billing: 73% of Q3 2025 revenue.
• International Sales: 18% of Q3 2025 revenue.
• U.S. O&P Channel Sales: 9% of Q3 2025 revenue.

The shift is defintely visible; the O&P channel is emerging as a high-quality, lower-cost source of qualified patients, which is a key strategic focus for Myomo, Inc. (MYO).

Finance: draft 13-week cash view by Friday.